🇺🇸 FDA
Patent

US 11633498

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

granted A61KA61K47/6807A61K47/6849

Quick answer

US patent 11633498 (Muscle targeting complexes and uses thereof for treating myotonic dystrophy) held by Dyne Therapeutics, Inc. expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K47/6807, A61K47/6849, A61K47/6889, A61P